Targeting the CD47-SIRPA Axis in Oncology Analytical Tool 2022: 70 Companies and Partners Developing 81 CD47-SIRPA Axis Targeting Drugs 76 in Active Development Across 28 Different Targets
Kort samengevat
/PRNewswire/ -- The "Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Prnewswire.
Lees het volledige bericht ↗